Clinical Updates on the Use of SGLT2 Inhibitors: Dawn of a New Era?

1.00 CME
1.00 CME with ABIM MOC
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Clinical Updates on the Use of SGLT2 Inhibitors: Dawn of a New Era?


Provider Statement

This continuing medical education activity is provided by vindico

Support Statement

This activity is supported by an educational grant from Merck & Co., Inc.

Activity Description

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering drugs used in the treatment of type 2 diabetes. Recent clinical trials of SGLT2 inhibitors have reported beneficial cardiovascular (CV) outcomes in patients with heart failure (HF) along with a reduced risk of hospitalization due to HF regardless of diabetes status. However, providers lack knowledge of new agents and emerging trials for glucose management with proven reduction in CV risk and how to use them for the treatment of type 2 diabetes. In this educational activity, expert clinicians discuss the latest updates on SGLT2 inhibitors.

Target Audience

The intended audience for this activity is cardiologists, endocrinologists, internists, and other health care professionals involved in the management of patients with heart failure.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Apply the knowledge of mechanism of action of sodium glucose co-transporter 2 (SGLT2) inhibitors and rationale for their use in HF.
  • Utilize the latest clinical evidence regarding the use of SGLT2 inhibitors for treating patients with HF with reduced (HFrEF) or preserved ejection fraction (HFpEF).
  • Examine the pleotropic benefits of SGLT2 inhibitors including their role in existing treatment paradigms for the management of patients with HF.

Activity Chair

Christopher P. Cannon, MD
Education Director, Cardiovascular Innovation
Preventive Cardiology Section, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, MA


Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Professor of Medicine
Harvard Medical School
Boston, MA

Ileana L. Piña, MD, MPH, FAHA, FACC
Clinical Professor of Medicine, Central Michigan University
Adjunct Professor, Case Western Reserve University
Mount Pleasant, MI


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Ronald A. Codario, Jr., MD


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abimSuccessful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, April 1, 2021, to April 1, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of the 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individulas have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Contracted Research: Abbott Medical Optics, Aimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, MyoKardia, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi-Aventis, Synaptic, The Medicines Company

Christopher P. Cannon, MD
Consulting Fee: Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Eli Lilly, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, Rhoshan, Sanofi
Contracted Research: Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, Novo Nordisk, Pfizer

Ileana L. Piña, MD, MPH, FAHA, FACC
No relevant financial relationships to disclose.

Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose. 

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at